Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective

Shigeo Fuji1,2, Jessica Cheng2,3, Kimikazu Yakushijin2,4, Chinadol Wanitpongpun2,5

1Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, 2Nutrition Support WG, Asia-Pacific Blood and Marrow Transplantation group, 3Bone Marrow Transplant & Haematology, St Vincent’s Public Hospital Sydney, Sydney, Australia, 4Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan, 5Hematology Unit, Department of Internal Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an integral part of the treatment strategy for patients with malignant or non-malignant hematological diseases. Clinical outcomes of patients undergoing allo-HSCT have significantly improved in recent decades. However, transplant-related morbidity and mortality remain major issues for allo-HSCT recipients.

With regard to nutrition, patients undergoing allo-HSCT are at high risk for malnutrition. It is expected that clinical practice concerning nutritional support in allo-HSCT has been improving in recent decades; however, no data directly support this expectation. One major issue is the lack of large-scale randomized prospective studies, resulting in a lack of well-established strategies in nutritional support during allo-HSCT. In some Asia-Pacific countries, a physician’s lack of knowledge of nutritional support may impede the application of nutritional support practices recommended by existing guidelines. Another barrier may be the lack of access to an adequately qualified or trained registered dietitian (RD) at allo-HSCT units. Adequate training in the nutritional management of allo-HSCT patients should be provided to all RDs working with HSCT. Herein, we summarize the information on nutritional support in allo-HSCT, focusing on an Asian perspective.

Key words nutritional support, allogeneic transplant, hyperglycemia, malnutrition

1. Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an integral part of the treatment strategy for patients with malignant or non-malignant hematological diseases. The clinical outcomes of patients undergoing allo-HSCT have improved significantly in recent decades1,2. However, morbidity and mortality undoubtedly remain major issues in allo-HSCT recipients.

Patients undergoing allo-HSCT are at high risk for malnutrition3,4. Although we expect that clinical practice relating to nutritional support in allo-HSCT has improved in recent decades, there is no evidence directly supporting this expectation. One major issue is the lack of large-scale randomized prospective studies, resulting in a lack of well-established strategies in nutritional support during allo-HSCT. Accordingly, data from studies in non-HSCT and allo-HSCT settings need to be collated. Herein, we summarize information on nutritional support in allo-HSCT, with emphasis on an Asian perspective.

2. Pre-transplant Nutritional Support

After the diagnosis of hematological malignancy, patients typically have a lead time up to allo-HSCT, and this interval varies among hematological diseases. For instance, patients with acute myeloid leukemia receive...
induction chemotherapy and a few courses of consolidation therapy before allo-HSCT, which takes approximately 3 months. Thus, there is sufficient time to intervene from the viewpoint of nutritional support during this period. Importantly, malnutrition should be avoided before allo-HSCT. Patients who undergo intensive chemotherapy are at a high risk of malnutrition. Various retrospective studies have reported the impact of pre-transplant malnutrition on clinical outcomes after allo-HSCT (Table 1). Furthermore, poor performance status during allo-HSCT is a well-established adverse prognostic factor. Accordingly, in such cases, intensive nutritional support incorporating rehabilitation should be undertaken to maintain good performance status. Malnutrition status, so-called "iatrogenic sarcopenia", needs to be avoided using appropriate nutritional support by collaborating with a multidisciplinary team, as generally recommended for medical inpatients. A recent study has reported the significant impact of pre-transplant sarcopenia on post-transplant clinical outcomes. The use of supplemental nutritional support to improve rehabilitation was beneficial in increasing lean body mass and other factors, such as muscle strength, a factor that should also be assessed in the field of hematology.

At the time of diagnosis of hematological malignancy, patients can begin a treatment pathway leading to allo-HSCT. Therefore, it is recommended that the nutritional status be assessed early at initial diagnosis, as stated in the European Society for Clinical Nutrition and Metabolism (ESPEN) and the American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines. Screening is usually performed by a registered dietitian (RD). Weight loss, low body mass index, reduced muscle mass, reduced food intake, and the presence of inflammation are key parameters often employed to diagnose malnutrition. Screening tools incorporating these parameters are commonly used to assess the nutritional status. It is important to regularly repeat assessments in patients who are planning to undergo HSCT to detect and identify any signs of malnutrition.

In addition, it is critical to improve preexisting metabolic syndrome before allo-HSCT, including diabetes mellitus and obesity. Diabetes mellitus (DM) is a well-known poor prognostic factor for allo-HSCT. Pre-transplant DM, which requires treatment, is a factor for the hematopoietic cell transplantation comorbidity index (HCT-CI). Other retrospective studies have also found that pre-transplant hyperglycemia was associated with poor clinical outcomes post-allo-HSCT. The most common cause of DM is type 2 DM, which can be improved by nutritional intervention, including lifestyle modifications such as dietary interventions and physical activity. Additionally, pre-transplant obesity is a well-known poor prognostic factor in allo-HSCT. Pre-transplant obesity is also a factor for HCT-CI. According to a few retrospective studies, pre-transplant obesity was associated with an increased risk of non-relapse mortality, although pre-transplant obesity was not associated with a poor clinical outcome in these studies.

In summary, assessment of nutritional status by an RD and consultation with a physiotherapist for rehabilitation are recommended during the diagnosis of hematological disease in transplant candidates. Interventions to improve pre-transplant nutritional status and performance status are crucial for improving clinical outcomes following allo-HSCT.

3. Early Period after Allo-HSCT

Patients who undergo allo-HSCT are at a high risk of morbidities and mortalities after allo-HSCT, particularly during the early period post-allo-HSCT. Nutritional support during this period is crucial for maintaining an adequately healthy nutritional status after allo-HSCT. First, total caloric intake should be closely monitored, and when total caloric intake becomes insufficient, nutritional support should be implemented to maintain adequate total caloric intake to meet estimated needs. The target total caloric intake can be determined using the Harris-Benedict formula or other formulas. If the oral caloric intake decreases, additional snacks, protein/caloric enrichment of food, or energy/protein-dense drinks can be supplemented. If the total caloric intake continues to be insufficient, artificial nutritional support such as enteral nutrition (EN) or parenteral nutrition (PN) can be initiated. In medical inpatients, the use of individualized nutritional support can improve important clinical outcomes, including overall survival, compared with the use of standard hospital food meals alone. Thus, in patients undergoing allo-HSCT, nutritional support options should also be applied.

Recently, various studies have reported the possible beneficial effect of EN after allo-HSCT. No published study has demonstrated the favorable effect of EN when compared with PN in prospective randomized controlled trials. However, retrospective studies have suggested that EN affords clinical benefits post-allo-HSCT. In detail, a French group reported that patients who received EN demonstrated a significantly lower incidence of severe acute graft-versus-host disease (GVHD) and death due to infectious diseases than those who received PN after allo-HSCT. Additionally, recent studies reporting the clinical relevance of microbiota supported the importance of EN in maintaining the microbiota status after allo-HSCT. Although
<table>
<thead>
<tr>
<th>Author</th>
<th>Journal</th>
<th>Body Weight Category</th>
<th>N</th>
<th>%</th>
<th>Acute GVHD</th>
<th>NRM/TRM</th>
<th>Relapse</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuji S, et al.</td>
<td>Bone Marrow Transplant</td>
<td>Underweight (BMI&lt;18.5)</td>
<td>1791</td>
<td>14.9</td>
<td>35.7%</td>
<td>12.7%</td>
<td>19.5%</td>
<td>49.4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal (18.5-25)</td>
<td>8444</td>
<td>70.1</td>
<td>38.3%</td>
<td>13.5%</td>
<td>21.9%</td>
<td>53.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overweight (25-30)</td>
<td>1591</td>
<td>13.2</td>
<td>42.2%</td>
<td>16.8%</td>
<td>25.1%</td>
<td>54.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obesity (30+)</td>
<td>224</td>
<td>1.9</td>
<td>37.6%</td>
<td>15.9%</td>
<td>23.0%</td>
<td>63.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>12050</td>
<td></td>
<td>P=0.002</td>
<td>P=0.004</td>
<td>P=0.002</td>
<td>P=0.002</td>
</tr>
<tr>
<td>Le Blanc K, et al.</td>
<td>Haematological</td>
<td>BMI&lt;20</td>
<td>88</td>
<td>16.2</td>
<td>47.0%</td>
<td>39.0%</td>
<td>36.0%</td>
<td>35.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMI 20-25</td>
<td>290</td>
<td>53.3</td>
<td>47.0%</td>
<td>39.0%</td>
<td>36.0%</td>
<td>35.0%</td>
</tr>
<tr>
<td>Hirose EY, et al.</td>
<td>Clin Nutri ESPEN 2019</td>
<td>Underweight (BMI&lt;18.5)</td>
<td>20</td>
<td>13.5</td>
<td>32.0%</td>
<td>29.0%</td>
<td>43.0%</td>
<td>30.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal (18.5-25)</td>
<td>61</td>
<td>41.2</td>
<td>21.0%</td>
<td>42.0%</td>
<td>63.0%</td>
<td>49.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overweight (25-30)</td>
<td>44</td>
<td>29.7</td>
<td>25.0%</td>
<td>20.0%</td>
<td>49.0%</td>
<td>30.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obesity (30+)</td>
<td>23</td>
<td>15.5</td>
<td>60.0%</td>
<td>24.0%</td>
<td>29.0%</td>
<td>20.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>148</td>
<td></td>
<td>P=0.11</td>
<td>P=0.15</td>
<td>P=0.12</td>
<td>P=0.041</td>
</tr>
<tr>
<td>Yang J, et al.</td>
<td>Eur J Clin Nutr 2017</td>
<td>Low and normal BMI</td>
<td>163</td>
<td>61.0</td>
<td>13.0%</td>
<td>6.0%</td>
<td>73.0%</td>
<td>63.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High BMI (BMI&gt;23)</td>
<td>104</td>
<td>39.0</td>
<td>19.0%</td>
<td>26.0%</td>
<td>75.0%</td>
<td>55.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>267</td>
<td></td>
<td>P=0.123</td>
<td></td>
<td>P=0.327</td>
<td>55.0%</td>
</tr>
<tr>
<td>Hadjib-abaie M, et al.</td>
<td>Clin Transplant 2011</td>
<td>Underweight (BMI&lt;18.5)</td>
<td>35</td>
<td>18.2</td>
<td>16.0%</td>
<td>29.0%</td>
<td>38.0%</td>
<td>30.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal (18-25)</td>
<td>96</td>
<td>50.0</td>
<td>29.0%</td>
<td>21.0%</td>
<td>30.0%</td>
<td>63.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overweight/obesity (25-30)</td>
<td>61</td>
<td>31.8</td>
<td>34.0%</td>
<td>25.0%</td>
<td>27.0%</td>
<td>60.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>192</td>
<td></td>
<td>P=0.007</td>
<td>P=0.010</td>
<td>P=0.288</td>
<td>52.0%</td>
</tr>
<tr>
<td>Navarro WH, et al.</td>
<td>Biol Blood Marrow Transplant 2010</td>
<td>Underweight (BMI&lt;18)</td>
<td>20</td>
<td>2.2</td>
<td>48.0%</td>
<td>28.0%</td>
<td>44.0%</td>
<td>52.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normal (18-25)</td>
<td>290</td>
<td>32.3</td>
<td>44.0%</td>
<td>36.0%</td>
<td>36.0%</td>
<td>60.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overweight (25-30)</td>
<td>287</td>
<td>32.0</td>
<td>46.0%</td>
<td>40.0%</td>
<td>31.0%</td>
<td>52.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obese (30+)</td>
<td>301</td>
<td>33.5</td>
<td>50.0%</td>
<td>46.0%</td>
<td>25.0%</td>
<td>47.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total</td>
<td>898</td>
<td></td>
<td>P=0.228</td>
<td>P=0.003</td>
<td>P=0.001</td>
<td>P=0.001</td>
</tr>
</tbody>
</table>

BMI, body mass index; GVHD, graft-versus-host disease; NRM, non-relapse mortality; TRM, transplant-related mortality; OS, overall survival
meeting full caloric needs with EN alone might be challenging, a degree of EN infusion, also known as trophic feeding, could be beneficial. Furthermore, a recent prospective study incorporating prebiotics suggested the beneficial impact of prebiotics using resistant starch and a commercially available prebiotic mixture in patients who underwent allo-HSCT, which shortened the duration of oral mucositis and diarrhea and reduced the incidence and severity of acute GVHD. The authors performed a detailed analysis of the microbiota, revealing that the microbial diversity, the population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. A similar beneficial effect of prebiotics has been previously reported. These results suggest a beneficial effect of prebiotics after allo-HSCT by maintaining the microbiota status, which should be assessed in large-scale studies in the future.

Hyperglycemia is another issue during the early phase after allo-HSCT. Several factors, including immunosuppressive drugs, PN, and inflammation, lead to elevated glucose levels post-allo-HSCT. Retrospective studies have shown that the presence of hyperglycemia or malglycemia during the early phase after allo-HSCT is associated with an inferior clinical outcome. The authors performed a detailed analysis of the microbiota, revealing that the microbial diversity, the population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. A similar beneficial effect of prebiotics has been previously reported. These results suggest a beneficial effect of prebiotics after allo-HSCT by maintaining the microbiota status, which should be assessed in large-scale studies in the future.

Hyperglycemia is another issue during the early phase after allo-HSCT. Several factors, including immunosuppressive drugs, PN, and inflammation, lead to elevated glucose levels post-allo-HSCT. Retrospective studies have shown that the presence of hyperglycemia or malglycemia during the early phase after allo-HSCT is associated with an inferior clinical outcome. Such adverse effects of post-transplant DM have also been observed in organ transplantation. No large-scale study has prospectively reported the benefits of intensive glucose control after allo-HSCT. One small study incorporated intensive glucose control post-allo-HSCT. The authors demonstrated the feasibility of intensive glucose control after allo-HSCT, suggesting the possible beneficial effects of intensive glucose control. The incidence of infectious disease was significantly lower in the intervention group than in the historical control group. Subsequently, a prospective multi-center study incorporating intensive glucose control post-allo-HSCT demonstrated a similar promising clinical outcome: low infectious disease and non-relapse mortality rates, considering that almost all of the patients in this study received a classical myeloablative conditioning regimen. Intriguingly, a recent study that prospectively assessed the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on the incidence of acute GVHD demonstrated a promising, low incidence of severe acute GVHD. The authors reported no data on glucose control, but it is expected that glucose levels would decrease when using an anti-hyperglycemic drug, such as a DPP-4 inhibitor. The benefits of incorporating DPP-4 inhibitors after allo-HSCT should be reassessed in future trials.

4. Long-term Follow-up Post-allo-HSCT

Patients who undergo allo-HSCT are at a high risk of long-term malnutrition long-term post-allo-HSCT. In addition, they are at risk for malnutrition secondary to chronic GVHD, particularly gastrointestinal chronic GVHD. Allo-HSCT recipients are also at risk for metabolic syndrome associated with drugs used for GVHD prophylaxis or treatment, such as systemic corticosteroids, calcineurin inhibitors, and mTOR inhibitors.

In outpatient clinics, access to routine monitoring of nutritional status in allo-HSCT recipients might be limited. However, as discussed above, patients are also at a high risk of malnutrition post-allo-HSCT, especially in the setting of chronic GVHD. Thus, it is recommended to incorporate routine nutritional status assessments by RDs as part of the patient’s long-term follow-up regimen.

Moreover, it is important to educate patients and family members regarding nutrition before discharge or during the post-transplant period. Nutrition education should include topics such as food safety, food hygiene, and food allergies. It is particularly crucial to educate recipients of cord blood transplants, as transplant-acquired food allergy could be a serious complication, and guidance regarding this issue is critical to mitigating the risk of such complications.

5. Barriers to Improving Clinical Practice in Relation to Nutritional Support post-allo-HSCT

As discussed above, various interventions can be employed to maintain the nutritional status of patients undergoing allo-HSCT. However, in real-world scenarios, there are various barriers to improving clinical practice following allo-HSCT. In some countries, a physician’s lack of knowledge regarding nutritional support may hinder the application of nutritional support practices recommended by guidelines, such as ESPEN or ASPEN, in patients who will receive allo-HSCT. In Asia-Pacific countries, another barrier may be the lack of access to adequately qualified or trained RDs at some allo-HSCT units. It is also highly recommended that adequate training in the nutritional management of allo-HSCT recipients be provided to all RDs working within institutions performing allo-HSCT. This is especially pertinent for those institutions or transplant centers that frequently perform allo-HSCT.

6. Conclusion

Undoubtedly, nutritional support in HSCT is crucial for optimizing the nutritional status of patients undergoing allo-HSCT. This is believed to contribute to improv-
ing clinical outcomes after allo-HSCT. However, clinical studies assessing the importance of each nutritional intervention are limited. Further studies focusing on nutritional support for HSCT are required.

Author Contributions

S.F. and J.C. planned and reviewed published papers, and all the authors wrote and reviewed the manuscript. All the authors approved the final version of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website.

References


57. Fuji S, Mori T, Khattry N, Cheng J, Do YR, Yakushijin K, et al. Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. Bone Marrow Transplant. 2015; 50: 100-5.


https://doi.org/10.31547/bct-2021-024
Copyright ©2022 Asia-Pacific Blood and Marrow Transplantation Group (APBMT). This is an open access article distributed under CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).